Sofinnova Investments related stories
All articles and analysis
Meet the LP: VenCapThe UK-based fund of funds leverages the data from its nearly 40-year history to focus on a smaller number of managers it believes will consistently outperform the venture market.
Side Letter: PE's $160trn grailPrivate equity's biggest hitters take aim at the $160 trillion retail market, according to panellists at IPEM Paris. Plus: PE and VC deal values hit a four-year low; and Australian private investments are outperforming publicly traded instruments. Here's today's brief, for our valued subscribers only.
Sofinnova Investments ends run of increasingly larger fundsThe firm closed on $500m for its 11th flagship vehicle, which had a target of $600m.
Sofinnova Investments taps Dupont as executive partnerPreviously, Dupont was global head of research & development and executive vice president at Atara Biotherapeutics.
PE is eating early-stage life sciences VCsApollo has announced it will buy a minority stake in Paris-based life sciences VC firm Sofinnova Partners, following Carlyle's purchase of Abingworth and EQT's acquisition of LSP.
Sofinnova Investments appoints Carpenter as exec partnerPrior to joining Sofinnova, he was chief medical officer at Catamaran Bio.
VC-backed CinCor prices IPOCinCor Pharma, a developer of treatment for hypertension and other cardio-renal diseases, has priced its IPO of 11 million shares at a price range between $15 and $17 per share.
- Omega Funds wraps up seventh fund at $650m
Omega Funds has closed its seventh fund at $650 million, beating its $500 million target.
- Sofinnova Ventures targets $600m for eleventh fund
Sofinnova Ventures is seeking to raise $600 million for its eleventh fund, according to an SEC filing.
VC-backed Vera Therapeutics goes publicSouth San Francisco-based Vera Therapeutics, a biotech company, has raised $47.85 million for its IPO after pricing its 4.35 million shares at $11 per share.